# A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma

> **NCT00452348** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 628 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
- **DRUG:** Fluticasone propionate 250 mcg BID

## Key facts

- **NCT ID:** NCT00452348
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 628 (ACTUAL)
- **Last updated:** 2016-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00452348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00452348, "A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT00452348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*